These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 8546166)

  • 21. Protein-bound uremic retention solutes.
    Brunet P; Dou L; Cerini C; Berland Y
    Adv Ren Replace Ther; 2003 Oct; 10(4):310-20. PubMed ID: 14681860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels.
    Galli F; Benedetti S; Buoncristiani U; Piroddi M; Conte C; Canestrari F; Buoncristiani E; Floridi A
    Kidney Int; 2003 Aug; 64(2):748-55. PubMed ID: 12846775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new polymethylmethacrylate membrane for hemodialysis.
    Bonomini M; Fiederling B; Bucciarelli T; Manfrini V; Di Ilio C; Albertazzi A
    Int J Artif Organs; 1996 Apr; 19(4):232-9. PubMed ID: 8786174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retention of an albumin-bound furan dicarboxylic acid in patients with chronic renal failure or after a kidney transplant.
    Costigan MG; Yaqoob M; Lindup WE
    Nephrol Dial Transplant; 1996 May; 11(5):803-7. PubMed ID: 8671898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of furancarboxylic acid, a candidate for uremic toxin, in human serum, hair, and sweat, and analysis of pharmacological actions in vitro.
    Sassa T; Matsuno H; Niwa M; Kozawa O; Takeda N; Niwa T; Kumada T; Uematsu T
    Arch Toxicol; 2000 Feb; 73(12):649-54. PubMed ID: 10741476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis.
    Fagugli RM; De Smet R; Buoncristiani U; Lameire N; Vanholder R
    Am J Kidney Dis; 2002 Aug; 40(2):339-47. PubMed ID: 12148107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, a major endogenous ligand substance in uremic serum, by high-performance liquid chromatography with ultraviolet detection.
    Mabuchi H; Nakahashi H
    J Chromatogr; 1987 Mar; 415(1):110-7. PubMed ID: 3584344
    [No Abstract]   [Full Text] [Related]  

  • 28. Association of advanced age with concentrations of uraemic toxins in CKD.
    Rroji M; Eloot S; Dhondt A; Van Biesen W; Glorieux G; Neirynck N; Vandennoortgate N; Liabeuf S; Massy Z; Vanholder R
    J Nephrol; 2016 Feb; 29(1):81-91. PubMed ID: 25857296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved dialytic removal of protein-bound uremic toxins by intravenous lipid emulsion in chronic kidney disease rats.
    Shi Y; Zhang Y; Tian H; Wang Y; Shen Y; Zhu Q; Ding F
    Nephrol Dial Transplant; 2019 Nov; 34(11):1842-1852. PubMed ID: 31071223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of protein leaking BK-F PMMA-based hemodialysis on plasma pentosidine levels.
    Tessitore N; Lapolla A; Aricò NC; Poli A; Gammaro L; Bassi A; Bedogna V; Corgnati A; Reitano R; Fedele D; Lupo A
    J Nephrol; 2004; 17(5):707-14. PubMed ID: 15593039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative contributions of body iron status and uremia severity to anemia in patients with advanced chronic renal failure.
    Ifudu O; Dawood M; Friedman EA
    Nephron; 1997; 77(3):315-8. PubMed ID: 9375826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dialyzable uremic solutes contribute to enhanced oxidation of serum albumin in regular hemodialysis patients.
    Terawaki H; Nakayama K; Matsuyama Y; Nakayama M; Sato T; Hosoya T; Era S; Ito S
    Blood Purif; 2007; 25(3):274-9. PubMed ID: 17460395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production.
    Itoh Y; Ezawa A; Kikuchi K; Tsuruta Y; Niwa T
    Anal Bioanal Chem; 2012 Jun; 403(7):1841-50. PubMed ID: 22447217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia.
    Takamura N; Maruyama T; Otagiri M
    Clin Chem; 1997 Dec; 43(12):2274-80. PubMed ID: 9439444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical evaluation of four different high-flux hemodialyzers under conventional conditions in vivo.
    Sombolos K; Tsitamidou Z; Kyriazis G; Karagianni A; Kantaropoulou M; Progia E
    Am J Nephrol; 1997; 17(5):406-12. PubMed ID: 9382156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure.
    Niwa T
    Semin Nephrol; 1996 May; 16(3):167-82. PubMed ID: 8734460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New approaches to the removal of protein-bound toxins from blood plasma of uremic patients.
    Sarnatskaya VV; Yushko LA; Sakhno LA; Nikolaev VG; Nikolaev AV; Grinenko DV; Mikhalovsky SV
    Artif Cells Blood Substit Immobil Biotechnol; 2007; 35(3):287-308. PubMed ID: 17573628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of binding site of uremic toxins on human serum albumin.
    Sakai T; Takadate A; Otagiri M
    Biol Pharm Bull; 1995 Dec; 18(12):1755-61. PubMed ID: 8787801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A major endogenous ligand substance involved in renal failure.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 49(4):277-80. PubMed ID: 3412543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of haemodialysis and continuous ambulatory peritoneal dialysis on the plasma clearance of an albumin-bound furan dicarboxylic acid.
    Costigan MG; Yaqoob M; Lindup WE
    Nephrol Dial Transplant; 1995; 10(5):648-52. PubMed ID: 7566577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.